{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/chilblains/","result":{"data":{"firstChapter":{"id":"541e07aa-8e84-55e1-817f-8d101eeb46fd","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 8529776f-79cf-4efe-b2fa-af8811a0a250 --><h1>Chilblains: Summary</h1><!-- end field 8529776f-79cf-4efe-b2fa-af8811a0a250 -->","htmlStringContent":"<!-- begin item f018c7cf-9e03-4038-8cfe-a3e6c2c28537 --><!-- begin field 61cab080-abd4-4824-90b9-e5ec3bef3c2d --><ul><li>Chilblains (also known as perniosis) are localized cold-induced inflammatory lesions, which affect areas of skin vulnerable to cold exposure such as the fingers, toes, nose, and ears.</li><li>Chilblains can be classified as acute or chronic:<ul><li>Acute chilblains develop within 12–24 hours of exposure to cold and usually resolve within 2–3 weeks, provided that further cold exposure is avoided. </li><li>Chronic chilblains are persistent lesions which can develop on repeated exposure to cold — in some cases leading to scarring and atrophy.</li></ul></li><li>Chilblains are thought to be caused by prolonged or intermittent cold-induced vasoconstriction of deep cutaneous arterioles with associated dilatation of smaller superficial vessels, in susceptible people.<ul><li>Primary or idiopathic chilblains are not associated with any underlying condition.</li><li>Secondary chilblains are associated with underlying conditions such as connective tissue or haematological disorders.</li></ul></li><li>Risk factors for chilblains include:<ul><li>Family history.</li><li>Peripheral vascular disease.</li><li>Low body weight or poor nutrition.</li></ul></li><li>Complications include:<ul><li>Skin excoriation from scratching.</li><li>Secondary infection from blistered or scratched chilblains.</li><li>Ulceration.</li><li>Permanent discolouration.</li><li>Scarring.</li></ul></li><li>Chilblains are usually diagnosed clinically and should be suspected in people with a history of recent (within 12–24 hours) cold exposure and red–purple macular, papular or nodular lesions on acral skin (most commonly the fingers and toes).<ul><li>Lesions are typically associated with pruritus and/or burning discomfort but may be asymptomatic.</li><li>Arterial circulation and peripheral sensation should be normal.</li><li>Further investigations/referral to the appropriate specialist is required if an underlying cause is suspected or the diagnosis is in doubt.</li></ul></li><li>People with idiopathic chilblains should be reassured that the condition is self limiting, caused by exposure to cold, and will resolve if further exposure to cold is avoided.</li><li>The following should be advised:<ul><li>Drying and gradually warming the skin — application of direct heat should be avoided.</li><li>Avoidance of smoking, if relevant.</li><li>Avoidance of cold, damp conditions (if possible) to prevent recurrence.</li><li>Wearing adequate clothing including warm gloves and socks.</li></ul></li><li>Drug treatment should not be routinely prescribed, but may be considered for severe chronic chilblains and recurrent episodes of severe chilblains that do not respond to appropriate self-care measures.<ul><li>Modified-release nifedipine (off-label indication) is an option but current evidence is based on small trials with conflicting results.</li></ul></li></ul><!-- end field 61cab080-abd4-4824-90b9-e5ec3bef3c2d --><!-- end item f018c7cf-9e03-4038-8cfe-a3e6c2c28537 -->","topic":{"id":"98f988ea-4ee8-52e9-8212-438a79499f92","topicId":"17adddaf-c9b6-4278-9b49-932d14f56439","topicName":"Chilblains","slug":"chilblains","aliases":[],"chapters":[{"id":"541e07aa-8e84-55e1-817f-8d101eeb46fd","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"e6b34a51-a690-5858-9a53-0dc5d5b0e608","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"5f3bae74-0385-5bf1-b250-9e74f16cfe18","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"4ae9419d-bc20-56ba-91a1-0420a339c087","slug":"changes","fullItemName":"Changes"},{"id":"e57dda70-8cbd-58d2-a2fb-8901c08e6853","slug":"update","fullItemName":"Update"}]},{"id":"ddec423e-57a6-54df-ba06-4014b41b839c","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"9315120c-762a-5273-867b-759b5537e4b8","slug":"goals","fullItemName":"Goals"},{"id":"666bca6f-0132-53bc-95cc-27fcbd0b4a96","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8b7e8a8e-c9dd-5555-8409-dfea005ea395","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fa795717-6d81-577e-b792-90e487b3895c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bff6f393-7347-51fa-8d46-95b80a272b9e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7da4aff5-e153-5f3f-bc51-0a943110c08d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1cc6d520-d1d7-5bcd-9d7c-b1352c82d453","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"bba6260f-6b68-52b5-88c0-17f3ba449705","slug":"definition","fullItemName":"Definition"},{"id":"f4b6f42f-60f1-56db-9cc2-c9d377ec6c5a","slug":"causes","fullItemName":"Causes"},{"id":"adb617b9-5304-53c4-8f1f-6aaec8a9c35b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16008222-9ac8-5d8e-9380-55d21f8ca4d9","slug":"complications","fullItemName":"Complications"},{"id":"16a3612e-723d-580a-a4c7-157274078ba8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4c9a7bb6-deca-5726-8c77-5c4cc1bfa2a1","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"468b6d0a-7e5f-59c0-affa-b0ee0c6eec91","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"08c8ac64-d612-5dfe-9926-2d0dfbc02f14","slug":"assessment","fullItemName":"Assessment"},{"id":"3db0f33f-97a0-5db2-83b8-ca9bb0e25bdc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ae9e38d9-23ba-50f8-8fd8-949711f14be6","slug":"management","fullItemName":"Management","subChapters":[{"id":"757e5e29-3beb-57b4-b55c-3050dd84bdc8","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"7f12498b-880e-5fca-908a-0c9547ba0d60","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"b6be7c9c-cf67-5a2d-abb4-b8edc8d404e9","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"c98234ab-a54f-5b11-bd3d-ddc791a382d6","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"1c4fbb70-40dc-5931-9e8e-6d8fdcd80db4","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a6193060-7713-5e53-9336-66e3cb961a3a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c1d12d25-39b2-5827-a25e-dcf5536bf470","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"435de6c9-1336-5c37-8c94-8ab2ee7f2adb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"cc4fe9b8-3554-5630-88cd-6dfee9d06235","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d1b809a-3a66-5daa-a184-7cdfb748fe77","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d01450d0-bab3-5fff-9ec6-40623a484024","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"98f988ea-4ee8-52e9-8212-438a79499f92","topicId":"17adddaf-c9b6-4278-9b49-932d14f56439","topicName":"Chilblains","slug":"chilblains","aliases":[],"topicSummary":"Chilblains (also known as perniosis or pernio) are localized inflammatory skin lesions on exposed extremities of the body, precipitated by cold.","lastRevised":"Last revised in June 2018","nextPlannedReviewBy":"2023-06-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2023-05","nextPlannedReviewByDisplay":"May 2023","specialities":[{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"}],"chapters":[{"id":"541e07aa-8e84-55e1-817f-8d101eeb46fd","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"e6b34a51-a690-5858-9a53-0dc5d5b0e608","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"5f3bae74-0385-5bf1-b250-9e74f16cfe18","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"4ae9419d-bc20-56ba-91a1-0420a339c087","slug":"changes","fullItemName":"Changes"},{"id":"e57dda70-8cbd-58d2-a2fb-8901c08e6853","slug":"update","fullItemName":"Update"}]},{"id":"ddec423e-57a6-54df-ba06-4014b41b839c","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"9315120c-762a-5273-867b-759b5537e4b8","slug":"goals","fullItemName":"Goals"},{"id":"666bca6f-0132-53bc-95cc-27fcbd0b4a96","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8b7e8a8e-c9dd-5555-8409-dfea005ea395","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fa795717-6d81-577e-b792-90e487b3895c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bff6f393-7347-51fa-8d46-95b80a272b9e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7da4aff5-e153-5f3f-bc51-0a943110c08d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1cc6d520-d1d7-5bcd-9d7c-b1352c82d453","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"bba6260f-6b68-52b5-88c0-17f3ba449705","slug":"definition","fullItemName":"Definition"},{"id":"f4b6f42f-60f1-56db-9cc2-c9d377ec6c5a","slug":"causes","fullItemName":"Causes"},{"id":"adb617b9-5304-53c4-8f1f-6aaec8a9c35b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16008222-9ac8-5d8e-9380-55d21f8ca4d9","slug":"complications","fullItemName":"Complications"},{"id":"16a3612e-723d-580a-a4c7-157274078ba8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4c9a7bb6-deca-5726-8c77-5c4cc1bfa2a1","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"468b6d0a-7e5f-59c0-affa-b0ee0c6eec91","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"08c8ac64-d612-5dfe-9926-2d0dfbc02f14","slug":"assessment","fullItemName":"Assessment"},{"id":"3db0f33f-97a0-5db2-83b8-ca9bb0e25bdc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ae9e38d9-23ba-50f8-8fd8-949711f14be6","slug":"management","fullItemName":"Management","subChapters":[{"id":"757e5e29-3beb-57b4-b55c-3050dd84bdc8","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"7f12498b-880e-5fca-908a-0c9547ba0d60","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"b6be7c9c-cf67-5a2d-abb4-b8edc8d404e9","slug":"nifedipine","fullItemName":"Nifedipine"}]},{"id":"c98234ab-a54f-5b11-bd3d-ddc791a382d6","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"1c4fbb70-40dc-5931-9e8e-6d8fdcd80db4","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"a6193060-7713-5e53-9336-66e3cb961a3a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c1d12d25-39b2-5827-a25e-dcf5536bf470","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"435de6c9-1336-5c37-8c94-8ab2ee7f2adb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"cc4fe9b8-3554-5630-88cd-6dfee9d06235","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2d1b809a-3a66-5daa-a184-7cdfb748fe77","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d01450d0-bab3-5fff-9ec6-40623a484024","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"98f988ea-4ee8-52e9-8212-438a79499f92"}},"staticQueryHashes":["3666801979"]}